Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid

@article{Cockbain2014AnticolorectalCA,
  title={Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid},
  author={A. Cockbain and M. Volpato and Amanda D. Race and A. Munarini and C. Fazio and A. Belluzzi and P. Loadman and G. Toogood and M. Hull},
  journal={Gut},
  year={2014},
  volume={63},
  pages={1760 - 1768}
}
Background Oral administration of the omega-3 fatty acid eicosapentaenoic acid (EPA), as the free fatty acid (FFA), leads to EPA incorporation into, and reduced growth of, experimental colorectal cancer liver metastases (CRCLM). Design: We performed a Phase II double-blind, randomised, placebo-controlled trial of EPA-FFA 2 g daily in patients undergoing liver resection surgery for CRCLM. The patients took EPA-FFA (n=43) or placebo (n=45) prior to surgery. The primary end-point was the CRCLM… Expand
The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid
TLDR
The data support the concept that EPA can be considered the “universal donor” with respect to key n-3 PUFAs and that this enteric-coated formulation allows long term treatment with a high level of compliance. Expand
Marine ω-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis
TLDR
High marine ω-3 PUFA intake after CRC diagnosis is associated with lower risk of CRC-specific mortality, and increasing consumption of marine υ3 PUFAs after diagnosis may confer additional benefits to patients with CRC. Expand
N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence
TLDR
The data support that EPA and/or DHA could be used to improve outcomes important to the patient and disease process, but before incorporation into treatment can occur, there is a need for larger, well-controlled, statistically powered randomized controlled trials to move n-3 supplementation to clinical practice. Expand
Investigation of resolvin E1 as a metabolite of eicosapentaenoic acid with anti-colorectal cancer activity
TLDR
The hypothesis was that RvE1 synthesised within CRC could induce CRC cell apoptosis through either or both ChemR23 and BLT1 receptor signaling, which was found to be expressed by human CRC clinical samples. Expand
Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases.
TLDR
There was a significant increase in RBC EPA in the EPA group, but not in the placebo arm, and the EPA level predicted tumour EPA content, which should be evaluated as a biomarker of tumour exposure and clinical outcomes in future EPA trials in CRC patients. Expand
A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
TLDR
Omega-3 PUFA supplementation induces a reversible increase in several short-chain fatty acid-producing bacteria, independently of the method of administration, as well as a reversible increased abundance of several genera, including Bifidobacterium and Lactobacillus. Expand
The ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cancer death in a Japanese community: The Hisayama Study
TLDR
It is suggested that decreased level of the serum EPA:AA ratio is a significant risk factor for cancer death in the general Japanese population. Expand
Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer
TLDR
Latest data regarding the effect of O3FAs on post-diagnosis CRC outcomes are reviewed, including mechanistic preclinical data, evidence that O 3FAs have beneficial effects on efficacy and tolerability of CRC chemotherapy, and human epidemiological data linking dietary O3FA intake with CRC outcomes. Expand
New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids.
TLDR
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acids, are recognized for their anti-inflammatory properties and have been used in therapeutic approaches to treat or attenuate cancer cachexia. Expand
n-3 PUFAs: an Elixir in Prevention of Colorectal Cancer
TLDR
The molecular mechanism of action of n-3 PUFAs on the chemoprevention of colon cancer is discussed, which can maintain the intestinal homeostasis by hampering the expression of the genes involved in inflammation, angiogenesis, and metastasis of Colon cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis
TLDR
EPA-FFA has chemopreventative efficacy in FAP, to a degree similar to that previously observed with selective cyclo-oxygenase-2 inhibitors, and holds promise as a colorectal cancer Chemoprevention agent with a favourable safety profile. Expand
Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.
TLDR
It is concluded that EPA-FFA drives a COX-2-dependent "PGE (2)-to-PGE(3) switch" in human CRC cells and that PGE (3) acts as a partial agonist at the PGE(2) EP4 receptor. Expand
Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer
TLDR
The mechanisms by which ω-3 PUFAs are thought to have antineoplastic activity are described and current clinical trials investigating the potential therapeutic role(s), at different stages of colorectal carcinogenesis, are summarised. Expand
Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids.
TLDR
Erythrocyte membrane EPA+DHA increases during relatively short intervals in response to supplementation at rates related to amount of supplementation, and may be useful to establish appropriate dosage for omega-3 fatty acid supplementation. Expand
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
TLDR
DHA during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when highly incorporated, suggesting DHA has a potential to specifically chemosensitise tumours. Expand
Bioavailability of long-chain omega-3 fatty acids.
TLDR
There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future. Expand
The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential.
TLDR
The conclusions drawn from this review suggest that omega-3 FAs in particular eicosapentaenoic acid (EPA) and docosahexaenoic Acid (DHA) found principally in oily fish have potent anti-angiogenic effects inhibiting production of many important angiogenic mediators. Expand
The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
TLDR
The absence of a significant, direct effect of rofecoxib on epithelial cells in liver metastases in vivo mirrors the lack of activity on human CRC cells at pharmacologically relevant concentrations in vitro. Expand
Modulation of angiogenesis by-3 polyunsaturated fatty acids is mediated by cyclooxygenases
The potential role of dietary fats in cancer is attracting considerable interest within the community. Both epidemiologic and experimental findings suggest that omega-3 polyunsaturated fatty acids (Expand
Mechanisms of action of (n-3) fatty acids.
  • P. Calder
  • Medicine, Biology
  • The Journal of nutrition
  • 2012
TLDR
The very long-chain (n-3) PUFA have a range of physiological roles that relate to optimal cell membrane structure and optimal cell function and responses, and play a key role in preventing, and perhaps treating, many conditions of poor health and well-being. Expand
...
1
2
3
4
...